SCHEMBL582707

SCHEMBL582707

CCn1ncc2c(Nc3cccnc3)c(C3=NOC4(CCCC4)C3)cnc21

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 13/20 0.40
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
PDE7A Q13946 2/20 0.37
BCDIN3D Q7Z5W3 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
MARK3 P27448 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL582462 0.99 PDE4B (0.39) PDE4BALDH1A1LMNAMAPTPDE7A
SCHEMBL583063 0.98 PDE4B (0.40) PDE4BALDH1A1LMNAMAPTPDE7A
SCHEMBL583252 0.91 PDE4B (0.48) PDE4BPDE7ABCDIN3DPDE3BPDE3A
SCHEMBL582969 0.90 PDE4B (0.39) PDE4BPDE7ABCDIN3DPDE3BPDE3A
SCHEMBL582884 0.90 PDE4B (0.48) PDE4BPDE7ABCDIN3DPDE3BPDE3A
SCHEMBL582476 0.89 PDE4B (0.39) PDE4BPDE7ABCDIN3DSIGMAR1PDE3B
SCHEMBL582987 0.89 PDE4B (0.39) PDE4BMAPTPDE7APDE3BPDE3A
SCHEMBL582190 0.89 PDE4B (0.48) PDE4BALDH1A1MAPTPDE7APDE3B
SCHEMBL582472 0.88 PDE4B (0.39) PDE4BPDE7ABCDIN3DPDE3BPDE3A
SCHEMBL582615 0.88 PDE4B (0.40) PDE4BMAPTPDE7APDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US claimed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP claimed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US claimed
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A PDE4B 5/4885ALDH1A1 1007/4885LMNA 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.